股东方面，截至2025年3月31日，维力医疗股东户数17604户，较上次增加318户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)38维力医疗16.0416.671.8836.58亿行业平均 50.9948.894.72108.92亿行业中值36.9038.892.4850.13亿1天益医疗-1803.12-3088.541.9222.98亿2澳华内 镜-687.21344.675.5172.42亿3诺唯赞-423.38-500.752.3290.60亿4爱朋医疗-414.76315.105.0034.03亿5博晖 创新-338.52537.183.6149.67亿6奥精医疗-157.17-230.362.0729.17亿7硕世生物-144.42-2110.301.2942.24亿 8睿昂基因-105.17-86.351.4913.61亿9康泰医学-87.11-73.603.1157.34亿10中红医疗-73.01-58.240.9250.74亿 11热景生物-65.79-75.804.85144.77亿 6月11日，维力医疗今日收盘12.4 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)38维力医疗15.4116.021.8135.14亿行业平均 49.6447.924.61106.85亿行业中值36.3637.152.4549.28亿1天益医疗-1776.29-3042.591.9022.64亿2澳华内 镜-644.66323.335.1667.94亿3诺唯赞-407.58-482.062.2487.22亿4爱朋医疗-359.62273.204.3329.51亿5博晖 创新-330.17523.933.5248.44亿6奥精医疗-139.08-203.851.8325.81亿7硕世生物-137.56-2010.081.2340.24亿 8睿昂基因-102.37-84.041.4513.25亿9康泰医学-89.13-75.303.1858.66亿10中红医疗-72.45-57.790.9250.35亿 11华大智造-55.85-49.563.85297.77亿 广州维力医疗器械股份有限公司的主营业务是麻醉、导尿、泌尿外科、护理、呼吸、血液透析等领域医 疗器械的研发、生产和销售，在临床上广泛应用于普通开放手术、微创手术，急救和护理等。公司的 ...

广州维力医疗器械股份有限公司的主营业务是麻醉、导尿、泌尿外科、护理、呼吸、血液透析等领域医 疗器械的研发、生产和销售，在临床上广泛应用于普通开放手术、微创手术，急救和护理等。公司的主 要产品是气管插管、喉罩、支气管插管、可视支气管插管、气管切开插管、麻醉面罩、人工鼻、麻醉呼 吸管路、电子镇痛泵、导尿管、导尿包、抗菌导尿管、测温导尿管、引流袋、男用导尿套、精密尿袋、 包皮环切缝合器、清石鞘、微创扩张引流套件、导丝、球囊扩张导管、输尿管扩张器、输尿管导引鞘、 取石篮、输尿管支架、输尿管导管、杨克引流管、口护吸痰管、排泄物管理器、氧气面罩、氧浓度可调 面罩、药物吸入雾化器、血液净化体外循环管路。 最新一期业绩显示，2025年一季报，公司实现营业收入3.48亿元，同比12.60%；净利润5892.38万元， 同比17.25%，销售毛利率44.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)40维力医疗15.6416.261.8335.67亿行业平均 48.7146.924.57105.44亿行业中值35.3737.132.4047.42亿1天益医疗-1727.26-2958.601.8422.01亿2 ...

5月12日，维力医疗今日收盘11.96元，上涨1.10%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到15.36倍，创24天以来新低，总市值35.03亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.84倍，行业中值36.59倍，维力医疗排 名第37位。 截至2025年一季报，共有12家机构持仓维力医疗，其中其他5家、基金4家、保险3家，合计持股数 16245.28万股，持股市值19.49亿元。 来源：金融界 广州维力医疗器械股份有限公司的主营业务是麻醉、导尿、泌尿外科、护理、呼吸、血液透析等领域医 疗器械的研发、生产和销售，在临床上广泛应用于普通开放手术、微创手术，急救和护理等。公司的主 要产品是气管插管、喉罩、支气管插管、可视支气管插管、气管切开插管、麻醉面罩、人工鼻、麻醉呼 吸管路、电子镇痛泵、导尿管、导尿包、抗菌导尿管、测温导尿管、引流袋、男用导尿套、精密尿袋、 包皮环切缝合器、清石鞘、微创扩张引流套件、导丝、球囊扩张导管、输尿管扩张器、输尿管导引鞘、 取石篮、输尿管支架、输尿管导管、杨克引流管、口护吸痰管、排泄物管理器、氧气面罩、氧浓度可调 面罩、药物吸入雾化器、血 ...

Investment Rating - The report maintains a "Recommended" rating for the company [1][9]. Core Views - The company is transitioning from low-cost to high-cost products, initiating a new phase of high growth despite facing external challenges in recent years [10][11]. - The overall profitability has significantly improved, with gross margins increasing from 43.2% in 2022 to 44.5% in 2024, despite revenue growth being impacted by external factors [2][41]. - Future growth is expected to be driven by the introduction of high-margin new products and the gradual reduction of the impact from anti-corruption measures in the domestic market [46][48]. Summary by Sections Product System Upgrade as Core Growth Driver - The company has focused on upgrading its product system across research, sales, and manufacturing, transitioning from a traditional low-value consumables company to a more innovative entity [15][16]. - R&D investment has increased from 0.42 billion in 2019 to 1.11 billion in 2024, with the R&D expense ratio rising from 4.3% to 7.4% [16][18]. Impact of External Factors on Performance - In 2023, external factors such as inventory destocking by overseas clients led to a decline in export revenue, which fell to 2.64 billion, a year-on-year decrease of 18% [1][31]. - Domestic sales were also affected by anti-corruption measures, resulting in a 15% year-on-year decline in the second half of 2023 [1][34]. Future Outlook and Margin Improvement - The report anticipates that the impact of anti-corruption will diminish, allowing for the accelerated introduction of high-margin new products, which will boost domestic sales and margins [46][48]. - The company is also expanding its overseas operations to mitigate geopolitical risks, with plans for new manufacturing facilities in Mexico and Southeast Asia [49][50]. Financial Forecast and Valuation - The projected total revenue for 2024 is 1.509 billion, with a year-on-year growth rate of 8.8%, and net profit is expected to reach 219 million, reflecting a 14% increase [4][12]. - The target price for the company's stock is set at 16 yuan, with a current price of 11.59 yuan, indicating significant upside potential [4][9].